BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36514219)

  • 21. Oncogenic KRAS drives radioresistance through upregulation of NRF2-53BP1-mediated non-homologous end-joining repair.
    Yang L; Shen C; Estrada-Bernal A; Robb R; Chatterjee M; Sebastian N; Webb A; Mo X; Chen W; Krishnan S; Williams TM
    Nucleic Acids Res; 2021 Nov; 49(19):11067-11082. PubMed ID: 34606602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NOX2 inhibition reduces oxidative stress and prolongs survival in murine KRAS-induced myeloproliferative disease.
    Aydin E; Hallner A; Grauers Wiktorin H; Staffas A; Hellstrand K; Martner A
    Oncogene; 2019 Feb; 38(9):1534-1543. PubMed ID: 30323311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of heterozygosity for Kras
    Ma Y; Li Y; Ling S; Li X; Kong B; Hu M; Huang P
    Biochem Biophys Res Commun; 2020 Jun; 526(4):880-888. PubMed ID: 32279996
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cryptotanshinone suppresses tumorigenesis by inhibiting lipogenesis and promoting reactive oxygen species production in KRAS‑activated pancreatic cancer cells.
    Terado T; Kim CJ; Ushio A; Minami K; Tambe Y; Kageyama S; Kawauchi A; Tsunoda T; Shirasawa S; Tanaka H; Inoue H
    Int J Oncol; 2022 Sep; 61(3):. PubMed ID: 35894141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
    Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
    Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. dCK negatively regulates the NRF2/ARE axis and ROS production in pancreatic cancer.
    Hu Q; Qin Y; Xiang J; Liu W; Xu W; Sun Q; Ji S; Liu J; Zhang Z; Ni Q; Xu J; Yu X; Zhang B
    Cell Prolif; 2018 Aug; 51(4):e12456. PubMed ID: 29701272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eicosapentaenoic Acid Inhibits
    Chiu CF; Hsu MI; Yeh HY; Park JM; Shen YS; Tung TH; Huang JJ; Wu HT; Huang SY
    Biomolecules; 2021 Mar; 11(3):. PubMed ID: 33801246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers.
    Mukhopadhyay S; Goswami D; Adiseshaiah PP; Burgan W; Yi M; Guerin TM; Kozlov SV; Nissley DV; McCormick F
    Cancer Res; 2020 Apr; 80(8):1630-1643. PubMed ID: 31911550
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atypical KRAS
    Hobbs GA; Baker NM; Miermont AM; Thurman RD; Pierobon M; Tran TH; Anderson AO; Waters AM; Diehl JN; Papke B; Hodge RG; Klomp JE; Goodwin CM; DeLiberty JM; Wang J; Ng RWS; Gautam P; Bryant KL; Esposito D; Campbell SL; Petricoin EF; Simanshu DK; Aguirre AJ; Wolpin BM; Wennerberg K; Rudloff U; Cox AD; Der CJ
    Cancer Discov; 2020 Jan; 10(1):104-123. PubMed ID: 31649109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Measurement of Reactive Oxygen Species by Fluorescent Probes in Pancreatic Cancer Cells.
    Luo Y; Wang D; Abbruzzese JL; Lu W
    Methods Mol Biol; 2019; 1882():207-219. PubMed ID: 30378057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hyperglycemia enhances pancreatic cancer progression accompanied by elevations in phosphorylated STAT3 and MYC levels.
    Sato K; Hikita H; Myojin Y; Fukumoto K; Murai K; Sakane S; Tamura T; Yamai T; Nozaki Y; Yoshioka T; Kodama T; Shigekawa M; Sakamori R; Tatsumi T; Takehara T
    PLoS One; 2020; 15(7):e0235573. PubMed ID: 32609742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ryanodine receptor 2 promotes colorectal cancer metastasis by the ROS/BACH1 axis.
    Chen T; Zhang X; Ding X; Feng J; Zhang X; Xie D; Wang X
    Mol Oncol; 2023 Apr; 17(4):695-709. PubMed ID: 36453019
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Relevance of Nrf2 Pathway and Autophagy in Pancreatic Cancer Cells upon Stimulation of Reactive Oxygen Species.
    Zhang L; Li J; Ma J; Chen X; Chen K; Jiang Z; Zong L; Yu S; Li X; Xu Q; Lei J; Duan W; Li W; Shan T; Ma Q; Shen X
    Oxid Med Cell Longev; 2016; 2016():3897250. PubMed ID: 26682003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kras(G12D) induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cells.
    Diersch S; Wirth M; Schneeweis C; Jörs S; Geisler F; Siveke JT; Rad R; Schmid RM; Saur D; Rustgi AK; Reichert M; Schneider G
    Oncogene; 2016 Jul; 35(29):3880-6. PubMed ID: 26592448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer.
    Yang J; Mo J; Dai J; Ye C; Cen W; Zheng X; Jiang L; Ye L
    Cell Death Dis; 2021 Nov; 12(11):1079. PubMed ID: 34775496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-tumor efficacy of a potent and selective non-covalent KRAS
    Hallin J; Bowcut V; Calinisan A; Briere DM; Hargis L; Engstrom LD; Laguer J; Medwid J; Vanderpool D; Lifset E; Trinh D; Hoffman N; Wang X; David Lawson J; Gunn RJ; Smith CR; Thomas NC; Martinson M; Bergstrom A; Sullivan F; Bouhana K; Winski S; He L; Fernandez-Banet J; Pavlicek A; Haling JR; Rahbaek L; Marx MA; Olson P; Christensen JG
    Nat Med; 2022 Oct; 28(10):2171-2182. PubMed ID: 36216931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CXCR2 signaling regulates KRAS(G¹²D)-induced autocrine growth of pancreatic cancer.
    Purohit A; Varney M; Rachagani S; Ouellette MM; Batra SK; Singh RK
    Oncotarget; 2016 Feb; 7(6):7280-96. PubMed ID: 26771140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ARID1A suppresses malignant transformation of human pancreatic cells via mediating senescence-associated miR-503/CDKN2A regulatory axis.
    Li ZY; Zhu SS; Chen XJ; Zhu J; Chen Q; Zhang YQ; Zhang CL; Guo TT; Zhang LM
    Biochem Biophys Res Commun; 2017 Nov; 493(2):1018-1025. PubMed ID: 28942143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heparin-binding epidermal growth factor-like growth factor eliminates constraints on activated Kras to promote rapid onset of pancreatic neoplasia.
    Ray KC; Moss ME; Franklin JL; Weaver CJ; Higginbotham J; Song Y; Revetta FL; Blaine SA; Bridges LR; Guess KE; Coffey RJ; Crawford HC; Washington MK; Means AL
    Oncogene; 2014 Feb; 33(7):823-31. PubMed ID: 23376846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.